Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

NetraMark Holdings Inc AINMF


Primary Symbol: C.AIAI

NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.


CSE:AIAI - Post by User

Post by MorganEarpon Feb 06, 2024 1:55pm
63 Views
Post# 35865739

THIS.....

THIS.....17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends. The trends and risks which are likely to impact the Issuer are detailed in the Issuer’s Management Discussion and Analysis (the “MD&A”) under the headings “Risk Factors” including: NetraMark has a history of operating losses and is still in the early stages of development. We have generated minimal revenue and have incurred, and continue to incur, significant expenses. Accordingly, we expect to continue FORM 7 – MONTHLY PROGRESS REPORT January 2015 Page 4 to incur operating losses over the next several years. Our operating expenses and net losses going forward may fluctuate significantly from quarter-to quarter and year-to-year. We anticipate that our operating expenses will increase in the foreseeable future as we continue to invest in and develop our NetraMark suite of products (the “NetraMark Products”); NetraAI, NetraPlacebo, NetraGPT, build the sales and marketing programs, hire additional data scientists, bioinformaticians, software engineers and other personnel.

https://webfiles.thecse.com/NetraMark_Holdings_Inc._-_2023_MDA_-_Sept_30_2023_Final.pdf?2ae7XFtCMLzwQ08.nCYPueVyFpthWrAX


<< Previous
Bullboard Posts
Next >>